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Abstract  
Aims:  
Impaired renal function increases hypoglycemia risk in type 2 diabetes (T2DM). 
Insulin glargine 300 U/mL (Gla-300) has previously demonstrated reduced 
hypoglycemia risk versus insulin glargine 100 U/mL (Gla-100). Therefore, we 
investigated the impact of renal function on the safety and efficacy of Gla-300 and 
Gla-100.  
Materials and Methods:  
A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 
and 3 trials (N=2496). Eligible participants, aged ≥18 years with a diagnosis of 
T2DM, were randomized to receive once-daily evening injections of Gla-300 or Gla-
100. Pooled results were assessed by two renal function subgroups: estimated 
glomerular filtration rate (eGFR) <60 and ≥60 mL/min/1.73 m2.  
Results:  
The decrease in HbA1c after 6 months and the proportion of individuals with T2DM 
achieving HbA1c targets were comparable between Gla-300 and Gla-100, for both 
renal function subgroups. There was a reduced risk of nocturnal (00:00–05:59 h) 
confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia with Gla-300 in both 
renal function subgroups (eGFR <60 relative risk [RR] 0.76 [95% CI 0.62–0.94] and 
≥60 0.75 [0.67–0.85]). For confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe 
hypoglycemia at any time of day (24 h) the hypoglycemia risk was lower with Gla-
  
300 versus Gla-100 in both the lower (RR 0.94 [0.86–1.03]) and higher (RR 0.90 
0.85–0.95]) eGFR subgroups. 
Conclusions:  
Gla-300 provided comparable glycemic control to Gla-100, while indicating a 
reduced overall risk of confirmed (≤70 and <54 mg/dL [≤3.9 and <3.0 mmol/L]) or 
severe hypoglycemia with no significant difference between renal function 
subgroups.  
  
  
Introduction 
Diabetes and chronic kidney disease (CKD) are common chronic comorbid 
conditions, with diabetic kidney disease accounting for approximately half of all end-
stage renal disease cases in developed countries.1 The US National Health and 
Nutrition Examination Survey (NHANES) reported that approximately 40% of survey 
participants with diabetes had CKD.2 Similarly, in the UK, CKD stage 3 was reported 
in approximately 29% of individuals with diabetes, versus approximately 7% of those 
without diabetes3, while CKD stage 4 and 5 was reported in 2.1% versus 0.2%, and 
0.3% versus 0.03% of individuals with and without diabetes, respectively.3 
Additionally, the incidence of CKD in diabetes may be under-reported, with one US 
primary care study indicating that CKD stages 1–5 affected 54% of individuals with 
type 2 diabetes (T2DM), although it had only been diagnosed in 12% of cases.4 
Rates of CKD are higher in elderly populations, and as the proportion of people aged 
over 60 years increases so will the rates of CKD.5 
 
Renal impairment complicates the management of diabetes because it increases the 
risk of hypoglycemia, is associated with increased risk of cardiovascular morbidity 
and mortality, and limits the options for glucose-lowering therapy.6-9 For example, 
cardiovascular disease has been reported in 53% of people with CKD,10 and as high 
as 59% of people who also have T2DM.4 The rate of hypoglycemia in people with 
diabetes and CKD can be double that of individuals without CKD,11 therefore the 
choice of glucose-lowering therapy should account for this increased risk.6, 8 
Additionally, dose adjustments, or even drug withdrawal, may be necessary, as the 
  
clearance of some therapies may be affected.8 However, there is a lack of evidence 
available, particularly from randomized clinical trials, to inform the choice of therapy 
and treatment goals in the management of diabetes in people with renal 
impairment,8 or regarding optimal glycemic control in individuals with diabetes and 
more advanced CKD, for whom HbA1c targets >7.0 % may be appropriate.8 
 
For people with T2DM and CKD, insulin remains an appropriate option when other 
agents such as metformin may be contraindicated or are used at lower than standard 
doses.12 While insulin requirements are generally lower in people with impaired renal 
function, there are no specific guidelines regarding insulin dose adjustment in this 
population other than general recommendations that glycemic targets should be 
individualized.8 Insulin glargine 300 U/mL (Gla-300), a second-generation basal 
insulin, provides a more stable and prolonged pharmacokinetic and 
pharmacodynamic (PK/PD) profile compared with insulin glargine 100 U/mL (Gla-
100).13 Data from the phase 3 EDITION 1, 2 and 3 clinical trials showed that over 6 
months, Gla-300 provided comparable glycemic control to Gla-100 in participants 
with T2DM, with less hypoglycemia.14-16 Given the reduced hypoglycemia risk with 
Gla-300 versus Gla-100, we were interested to see if this benefit persisted in 
individuals with impaired renal function. The objective of this post hoc patient-level 
meta-analysis of EDITION 1, 2 and 3 was to investigate the impact of renal function 
on the safety and efficacy of Gla-300, with a focus on hypoglycemia risk. 
 
  
Materials and Methods 
Study design and participants
 
EDITION 1, 2 and 3 (NCT01499082, NCT01499095, NCT01676220) were 
multicenter, randomized (1:1), open-label, two-arm, parallel-group, phase 3a 
studies.14-16 Briefly, eligible participants were aged ≥18 years with T2DM and 
receiving the following: EDITION 1, basal (≥42 U/day) and prandial insulin therapy ± 
metformin for ≥1 year; EDITION 2, basal insulin therapy (≥42 U/day) in combination 
with OADs; EDITION 3, OADs received for ≥6 months before screening and insulin-
naïve. People with severe, unstable or end-stage renal disease (CKD stage 5, 
estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m2) were excluded. 
Participants were randomized (1:1) to once-daily evening injections of Gla-300 
(Toujeo, Sanofi, Paris, France) or Gla-100 (Lantus, Sanofi), titrated to a fasting 
self-monitored plasma glucose (SMPG) target of 80–100 mg/dL (4.4–5.6 mmol/L); 
sulfonylurea use was not allowed. 
 
In this post hoc analysis, study populations were pooled and results assessed across 
two renal function subgroups, according to baseline eGFR (calculated using the 
Modification of Diet in Renal Disease [MDRD] study equation): ≥15 to <60 (CKD 
stage 3–4, indicating mild-to-moderate renal impairment) and ≥60 mL/min/1.73 m2 
(indicating preserved renal function). 
 
  
Outcomes 
The following endpoints were examined: HbA1c and fasting plasma glucose (FPG) 
change from baseline to month 6, percentage of participants achieving HbA1c <7.0 % 
and <7.5 % at month 6, percentage of participants attaining FPG <5.6 mmol/L and 
<6.7 mmol/L, change in insulin dose and body weight from baseline to month 6, 
percentage of participants with ≥1 hypoglycemic event, hypoglycemic event rates per 
participant-year and cumulative mean number of hypoglycemic events per 
participant (during the night [00:00–05:59 h] or at any time of day [24 h]), and 
adverse events during the 6-month study period. Hypoglycemia endpoints were 
based on American Diabetes Association (ADA) definitions 17; confirmed or severe 
hypoglycemia was defined as any event that was documented symptomatic or 
asymptomatic with a plasma glucose measurement of ≤70 mg/dL or <54 mg/dL, or 
severe (requiring third-party assistance). 
 
Data analysis and statistics 
Efficacy outcomes were analyzed using the modified intent-to-treat (mITT) 
population, defined as all randomized participants who received at least one dose of 
study insulin and had both a baseline and at least one post-baseline efficacy 
assessment. The safety population comprised all participants who had received at 
least one dose of study insulin.  
 
  
Change in HbA1c was analyzed using a mixed model for repeated measurements 
(MMRM) approach. Relative risk of hypoglycemia was analyzed using the Cochran-
Mantel-Haenzel (CMH) method and annualized rates of hypoglycemia were 
analyzed using an overdispersed Poisson regression model. For HbA1c, and 
hypoglycemia, the homogeneity of the treatment effect among subgroups was 
assessed using subgroup-by-treatment interaction. Differences of treatment effect 
across subgroups were only considered relevant if significant heterogeneity was 
observed (p<0.05). Body weight, insulin dose, FPG, AEs and patient satisfaction 
(evaluated using the Diabetes Treatment Satisfaction Questionnaire [DTSQ]) were 
assessed descriptively. 
 
Results 
Baseline characteristics 
The mITT and safety populations included 2474 and 2488 individuals, respectively. 
Of the 2496 participants randomized to treatment in EDITION 1, 2 and 3, 2075 
(83.1%) had a baseline eGFR ≥60 mL/min/1.73 m2 (Gla-300: n=1039; Gla-100: 
1036) and 421 (16.9%) had a baseline eGFR <60 mL/min/1.73 m2 (Gla-300: n=208; 
Gla-100: 213). Baseline characteristics are summarized in Table 1. Participants 
were, on average, older in the lower versus higher eGFR subgroup (approximately 
65 years versus 57 years). Most participants in the study were Caucasian. Mean 
duration of diabetes was longer in the lower versus higher eGFR subgroup 
(approximately 16 years versus 12 years). Those in the lower eGFR subgroup had 
  
received approximately 1 year more of insulin therapy than those in the higher eGFR 
subgroup.  
 
The proportions of participants with comorbidities reported at baseline were similar 
between renal function subgroups (Supplementary Table 1), although there was a 
general trend for more participants reporting complications in the lower eGFR 
subgroup. The most common overall complication was diabetic sensory and motor 
neuropathy, reported in approximately 41% and 32% of participants in the lower and 
higher eGFR subgroups, respectively. Diabetic macroangiopathy was reported in an 
average of 9.1% and 6.1% of participants in the lower and higher eGFR subgroups, 
respectively (Supplementary Table 1). Cardiac disorders were documented in 39.2% 
of participants in the lower eGFR subgroup, compared with 25.4% in the higher 
eGFR subgroup.  
 
Renal function 
The EDITION 1 study contributed the largest proportion of participants to the <60 
mL/min/1.73 m2 subgroup (n=188) (Supplementary Table 2). At baseline, the pooled 
average eGFR for the lower and higher renal function subgroups were 48.6 
mL/min/1.73 m2 and 85.0 mL/min/1.73 m2, respectively. These values did not change 
markedly after 6 months’ treatment, regardless of eGFR subgroup or treatment arm 
(50.5 mL/min/1.73 m2 and 85.0 mL/min/1.73 m2). 
 
  
Previous and concomitant medications 
At baseline, most participants were using non-insulin antihyperglycemic medications 
(approximately 75% and 88% in the lower and higher eGFR subgroups, 
respectively), of which metformin was the most common (Table 1). The proportion of 
participants using metformin in the lower eGFR subgroup (55%) was less than in the 
higher eGFR subgroup (68%). By comparison, more participants in the lower eGFR 
subgroup than in the higher eGFR subgroup had previously been using insulins 
(72% and 63%, respectively) or antihypertensive agents (86% and 74%, 
respectively). Most participants were using statins, irrespective of renal function 
(Table 1). At month 6, there was very little change in medication usage patterns from 
baseline in either treatment arm or renal function subgroup (Supplementary Table 3).  
 
Glycemic control 
HbA1c reduction from baseline was comparable between the Gla-300 and Gla-100 
treatment groups, regardless of renal function (Least Squares [LS] mean difference 
0.14 [95% confidence interval (CI): –0.04 to 0.32 and –0.03 [95% CI: –0.11 to 0.05]) 
in the eGFR <60 and ≥60 subgroups, respectively. There was no evidence of 
heterogeneity of treatment effect across subgroups (p=0.097; Figure 1A). Similar 
proportions of participants achieved HbA1c target <7.0 % between treatment arms in 
both renal function subgroups. In the lower eGFR subgroup, 36.4% and 39.2% of 
participants achieved target with Gla-300 and Gla-100, respectively. In the higher 
eGFR subgroup, 36.2% and 34.7% of participants achieved target with Gla-300 and 
Gla-100 (Figure 1B). As observed for the HbA1c <7.0 % target, the proportion of 
  
participants achieving HbA1c target <7.5 % was comparable between the Gla-300 
and Gla-100 treatment arms in both renal function subgroups. In the Gla-300 and 
Gla-100 treatment arms respectively, 54.9% and 58.4% of participants achieved 
target in the lower eGFR subgroup, and 54.0% and 51.8% of participants achieved 
target in the higher eGFR subgroup. The mean change in FPG from baseline to 
month 6 was comparable for both treatment arms and renal function subgroups 
(Supplementary Table 4). The proportion of participants attaining FPG <5.6 mmol/L 
was 24.8% and 32.5% in the lower eGFR subgroup, and 25.2% and 25.1% in the 
higher eGFR subgroup, with Gla-300 and Gla-100, respectively; for attainment of 
FPG <6.7 mmol/L, the proportions were 45.1% and 50.2% in the lower eGFR 
subgroup, and 44.5% and 46.6% in the higher eGFR subgroup, with Gla-300 and 
Gla-100, respectively.  
 
Hypoglycemia 
More participants in the lower versus the higher eGFR subgroup experienced ≥1 
confirmed (≤70 mg/dL [≤3.9 mmol/L] and <54 mg/dL [<3.0 mmol/L]) or severe 
hypoglycemic event at night (00:00–05:59 h) or at any time of day (24 h), regardless 
of the insulin used (Figure 2A). The relative risk of confirmed (≤70 mg/dL [≤3.9 
mmol/L]) or severe hypoglycemic events at night (00:00–05:59 h) was lower with 
Gla-300 than with Gla-100 RR 0.76 [95% CI: 0.62 to 0.94] and 0.75 [95% CI: 0.67 to 
0.85] in the lower and higher eGFR subgroups, respectively. Similarly, the risk of any 
time of day (24 h) confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemic 
events was lower with Gla-300 than with Gla-100 in the lower and higher eGFR 
  
subgroups (RR 0.94 [95% CI 0.86 to 1.03 and 0.90 [95% CI 0.85 to 0.95], 
respectively). There was no significant difference between renal function subgroups 
(no evidence of heterogeneity of treatment effect across subgroups, p=0.662 for 
nocturnal events; p=0.794 for events at any time of day). Consistent results were 
observed when using the more stringent glycemic threshold of <54 mg/dL (<3.0 
mmol/L) (Figure 2B). 
 
The rates of confirmed or severe nocturnal (00:00–05:59 h) or any time (24 h) 
hypoglycemia events per participant-year, at both glycemic thresholds, were higher 
in the lower versus the higher eGFR subgroup, irrespective of the insulin used 
(Figure 3A). The annualized rate of confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe 
hypoglycemic events at night (00:00–05:59 h) and at any time of day (24 h) in the 
overall population was lower with Gla-300 than with Gla-100 (Figure 3B), and there 
was no significant difference between renal function subgroups (no evidence of 
heterogeneity of treatment effect across subgroups, p=0.986 for nocturnal events; 
p=0.604 for events at any time of day). The rate ratio of nocturnal confirmed (≤70 
mg/dL [≤3.9 mmol/L]) or severe hypoglycemic event was 0.69 [95% CI: 0.44 to 1.08] 
in the lower and 0.69 [95% CI: 0.56–0.85] in the higher eGFR subgroup. Similarly, 
for any time of day (24 h) confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe 
hypoglycemia the rate ratios for Gla-300 versus Gla-100 were 0.81 [95% CI:0.64 to 
1.04] in the lower eGFR subgroup and 0.88 [95% CI: 0.77 to 1.00] in the higher 
eGFR subgroup. Generally, these results were consistent at the lower glucose 
threshold, with an overall lower annualized rate of nocturnal events for Gla-300 
versus Gla-100, but not for hypoglycemic events that occurred at any time of day 
  
(Figure 3B), and no heterogeneity of treatment effect across the subgroups (p=0.707 
for nocturnal events; p=0.792 for events at any time of day). 
 
Severe hypoglycemia was experienced by 28/1242 (2.3%) participants in the 
Gla-300 group (lower eGFR subgroup: 11/207 [5.3%]; higher eGFR subgroup: 
17/1035 [1.6%]) and 33/1236 (2.6%) in the Gla-100 group (lower eGFR subgroup: 
9/212 [4.2%]; higher eGFR subgroup: 24/1034 [2.3%]). Annualized rates of severe 
hypoglycemic events at any time of day (24 h) were 0.35 and 0.26 events per 
participant-year in the Gla-300 and Gla-100 treatment groups, respectively, for 
participants in the lower eGFR subgroup. For the higher eGFR subgroup, annualized 
rates were 0.06 and 0.08 events per participant-year, respectively.  
 
The proportion of participants who achieved HbA1c targets (<7.0 % or <7.5 %) 
without experiencing confirmed or severe hypoglycemia were comparable across 
renal function subgroups and between treatment arms, for both hypoglycemia 
thresholds evaluated (Supplementary Table 5).  
 
Body weight and insulin dose 
Mean (SD) change in body weight from baseline to month 6 was small in both 
treatment groups across both renal function subgroups: 0.14 (4.06) kg and 0.42 
(3.68) kg for participants in the lower eGFR subgroup; 0.59 (3.48) kg and 0.92 (3.20) 
  
kg for participants in the higher eGFR subgroup, in the Gla-300 and Gla-100 groups, 
respectively. At month 6, insulin dose in the lower eGFR subgroup increased from 
baseline by 0.30 and 0.21 U/kg (an average increase of 89.3% and 72.4%) for 
Gla-300 and Gla-100, respectively. In the higher eGFR subgroup, the insulin dose 
increase from baseline was 0.35 and 0.26 U/kg (an average increase of 117.0% and 
89.2%) for Gla-300 and Gla-100, respectively (Supplementary Table 4). This 
reflected a −23.7% difference in dose increase for Gla-300 and a −18.8% difference 
in dose increase for Gla-100 between the lower versus higher eGFR subgroups.  
 
Adverse events 
Treatment-emergent adverse events (TEAEs) were observed more commonly in 
participants in the eGFR <60 versus the ≥60 mL/min/1.73 m2 subgroup. In the lower 
eGFR subgroup, TEAEs were reported in 64.7% and 59.4% of participants in the 
Gla-300 and Gla-100 treatment groups, respectively. In the higher eGFR subgroup, 
TEAEs were reported in 55.8% and 52.5% of participants in the Gla-300 and Gla-
100 treatment groups, respectively. The proportion of participants who experienced 
at least one TEAE relating to injection site reaction, hypersensitivity, cardiovascular 
events, and acute kidney injury, are shown in Supplementary Table 6. 
 
Participant satisfaction 
There were no differences in patient satisfaction either by eGFR subgroup or 
treatment arms. The mean (SD) change in total DTSQ score from baseline to month 
  
6 in the higher eGFR subgroup was 3.53 (6.50) and 3.93 (6.84) with Gla-300 and 
Gla-100, respectively. In the lower eGFR subgroup, mean change was 3.01 (6.43) 
and 3.30 (6.44) with Gla-300 and Gla-100, respectively. The LS mean difference 
(SE) between Gla-300 vs Gla-100 in total DTSQ scores after 6 months of treatment 
was −0.22 (0.21) in the higher eGFR subgroup, compared with −0.33 (0.46) in the 
lower eGFR subgroup.  
 
Discussion 
This patient-level meta-analysis from the EDITION 1, 2 and 3 trials of participants 
with T2DM by baseline eGFR subgroup demonstrated consistent and comparable 
reductions in FPG and HbA1c levels for the Gla-300 and Gla-100 groups, regardless 
of renal function subgroup. This finding was accompanied by a lower risk of 
nocturnal confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia with Gla-300 
than Gla-100, which was not influenced by renal function. Hence, overall the pooled 
results presented here are consistent with the individual EDITION studies,14-16 which 
also reported comparable glycemic control and reduced risk of hypoglycemia with 
Gla-300 compared with Gla-100. Importantly, however, these data show that this 
advantage of Gla-300 over Gla-100 was maintained in people with T2DM and 
impaired renal function. While the results of this patient-level meta-analysis are 
encouraging and suggest that Gla-300 therapy may also be used in people with 
T2DM and renal impairment, the scarcity of literature on insulin use in this 
population, and the post hoc nature of this analysis, highlight the need for 
  
randomized clinical trials to more fully evaluate the impact of renal function and CKD 
on diabetes therapy. 
 
As expected, participants with lower eGFR experienced higher incidence and rates 
of hypoglycemia. While the mean insulin doses increased in both treatment arms, 
there was a tendency for a larger increase with Gla-300, consistent with findings 
reported for the overall EDITION population.14-16 Although speculative, one possible 
reason underlying this greater increase in dose with Gla-300 than Gla-100 may be 
related to the lower bioavailability of Gla-300, owing to the greater stability of its 
subcutaneous depot that might make it more prone to enzymatic inactivation 
compared with Gla-100.18 It is also important to consider that the dose changes 
observed may be a consequence of the treat-to-target design of the EDITION trials; 
dose increases were to be expected given that participants switched to, or initiated, a 
new basal insulin in this study because they were uncontrolled on their previous 
treatment. In a meta-analysis of the EDITION studies, Gla-300 was associated with 
lower weight gain despite higher doses compared with Gla-100,18 and the current 
analysis demonstrates a similar trend in participants with renal impairment. 
 
Of note, the higher insulin doses observed in the EDITION studies with Gla-300 were 
not associated with an increased risk of hypoglycemic events, and the mean insulin 
doses were comparable between renal function subgroups in this analysis. 
Differences between renal function subgroups in the relative increases of insulin 
dose are unlikely to account for the higher incidence of hypoglycemia in the lower 
  
eGFR subgroup as, if anything, dose increases were lower in the <60 mL/min/1.73 
m2 than the ≥60 mL/min/1.73 m2 subgroup. Furthermore, the pooled data show that 
renal function did not change after treatment with either Gla-300 or Gla-100 for 6 
months. These findings suggest that the observed differences between the renal 
subgroups in the rate and incidence of hypoglycemia were unlikely to be related to 
dose or dose increase, but are consistent with the higher risk for hypoglycemia 
reported in CKD.11 In terms of safety, as expected, TEAE incidence was generally 
higher in the lower versus the higher eGFR subgroup, but there were no major 
differences in TEAEs between Gla-300 and Gla-100 within the two subgroups, nor 
between either renal function or treatment groups for injection site reactions, 
hypersensitivity, cardiovascular events or acute kidney injury.  
 
The 2016 ADA guidelines do not include specific HbA1c targets for individuals with 
T2DM and renal impairment, although goals that are less stringent than the general 
target of 7.0 % (e.g. <8.0 %) are suggested for people with comorbidities.21 Indeed, 
the current analysis demonstrates that HbA1c targets of <7.5 % are achievable for 
many people with T2DM. Furthermore, the reduced risk of hypoglycemia with Gla-
300 is particularly important in this patient group, where there is a high risk of 
cardiovascular disease, as the experience of hypoglycemia may be associated with 
cardiovascular events and mortality.22 
 
This post hoc analysis provides data supporting the use of Gla-300 in individuals 
with T2DM and mild renal impairment, which will help inform and guide management 
  
decisions. The comparison with Gla-100 is important, as this is the gold standard of 
treatment in many countries. The lower risk of hypoglycemia with Gla-300 than 
Gla-100 is of particular interest as the risk of hypoglycemia is increased in people 
with renal impairment,11 therefore therapy options with lower risk of hypoglycemia 
may be particularly beneficial in this population. Basal insulin therapy requires a 
balance between achieving appropriate individualized glycemic targets and 
minimizing or avoiding hypoglycemia. Consistent with the data here in participants 
with impaired renal function, a meta-analysis of EDITION 1, 2 and 3 data indicated 
that treatment with Gla-300 could allow people with T2DM to achieve equivalent 
glycemic control vs Gla-100 but with less hypoglycemia.23 
 
The limitations of this analysis included its post hoc nature and the exclusion of 
participants with severe renal impairment (CKD stage 5) from the EDITION program. 
In addition, the lower number of participants with eGFR <60 mL/min/1.73 m2 
compared with the ≥60 mL/min/1.73 m2 subgroup lead to wider confidence intervals 
for the hypoglycemia results for this subgroup compared with the ≥60 mL/min/1.73 
m2 subgroup, although the absolute point estimates were similar between each 
subgroup (Figures 2B and 3B). However, this analysis provided hypothesis-
generating data that may be explored further by stratifying participants according to 
renal function in future randomized controlled clinical studies, dedicated to evaluating 
insulin treatment in participants with T2DM. 
 
  
In summary, as previously demonstrated overall in the EDITION program, Gla-300 
had comparable effectiveness as Gla-100 in improving glycemic control in a group of 
challenging to treat people with T2DM and renal impairment; this clinical goal was 
achieved in tandem with a consistent overall reduction in the risk of nocturnal 
confirmed (≤70 and <54 mg/dL [≤3.9 and <3.0 mmol/L]) or severe hypoglycemia, 
with no significant difference between renal function subgroups.  
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Figure Legends 
Figure 1A. Mean change in HbA1c from baseline to month 6 according to renal 
function subgroup (mITT population) 
CI, confidence interval; LS, least squares; eGFR, estimated glomerular filtration rate; 
mITT, modified intent-to-treat; MMRM, mixed model for repeated measurements; 
†Logistic method; p<0.05 corresponds to significant heterogeneity of treatment effect 
 
Figure 1B. Percentage of participants achieving HbA1c targets (<7.0 % [53 mmol/mol] 
and <7.5 % [58.5 mmol/mol]) at month 6 (mITT population) 
eGFR, estimated glomerular filtration rate; mITT, modified intent-to-treat;  
 
Figure 2A. Percentage of participants experiencing ≥1 confirmed or severe 
hypoglycemic event (safety population) 
eGFR, estimated glomerular filtration rate 
 
Figure 2B. Relative risk of experiencing ≥1 hypoglycemic event with Gla-300 versus 
Gla-100 by renal function subgroup (safety population) 
CI, confidence interval; eGFR, estimated glomerular filtration rate; †Logistic method; 
p<0.05 corresponds to significant heterogeneity of treatment effect 
  
 
Figure 3A. Rate of confirmed or severe hypoglycemia by renal function subgroup 
(safety population)  
eGFR, estimated glomerular filtration rate 
 
Figure 3B. Ratio of annualized hypoglycemia event rates by renal function subgroup 
(safety population) 
CI, confidence interval; eGFR, estimated glomerular filtration rate; †Logistic method; 
p<0.05 corresponds to significant heterogeneity of treatment effect
  
Table 1. Baseline demographics and participant characteristics, by renal function subgroup (pooled 
randomized population) 
Renal function subgroups, 
baseline eGFR 
(mL/min/1.73 m2) 
<60 ≥60 
 Gla-300 
(N=208) 
Gla-100 
(N=213) 
Gla-300 
(N=1039) 
Gla-100 
(N=1036) 
Mean age, years 65.0 (7.9) 65.0 (7.5) 57.4 (9.0) 57.2 (9.3) 
Gender (male), n (%) 109 (52.4) 101 (47.4) 548 (52.7) 548 (52.9) 
Race, n (%) 
  
Caucasian/White 188 (90.4) 199 (93.4) 908 (87.4) 896 (86.5) 
Black 13 (6.3) 5 (2.3) 77 (7.4) 89 (8.6) 
Asian/Oriental 4 (1.9) 7 (3.3) 44 (4.2) 42 (4.1) 
Other 3 (1.4) 2 (0.9) 10 (1.0) 9 (0.9) 
Body weight, kg 101.2 (21.3) 99.5 (20.5) 99.6 (23.2) 99.9 (22.0) 
BMI, kg/m2 35.5 (7.0) 35.4 (6.3) 34.5 (6.9) 34.7 (6.4) 
Estimated GFR, 
mL/min/1.73 m2 49.0 (8.5) 48.2 (9.6) 85.1 (16.6) 85.0 (16.6) 
HbA1c, %  8.2 (0.8) 8.1 (0.8) 8.3 (0.9) 8.4 (0.9) 
HbA1c, mmol/mol 66.3 (9.2) 65.2 (8.3) 67.5 (10.2) 67.9 (10.1) 
  
Hemoglobin, g/L 
Males 138.4 (14.3) 140.3 (15.8) 146.0 (11.6) 145.6 (12.1) 
Number of males below 
gender specific range, n 
(%) 
19 (17.4) 17 (16.8) 22 (4.0) 26 (4.7) 
Females 128.2 (13.4) 128.3 (12.32) 132.6 (11.3) 132.3 (12.0) 
Number of females below 
gender specific range, n 
(%) 
15 (15.2) 18 (16.1) 33 (6.7) 35 (7.2) 
Albumin creatinine ratio 
assessed, n 
201 210 1018 1013 
  
Categories     
<30 mg/g, n (%) 120 (59.7) 136 (64.8) 777 (76.3) 784 (77.4) 
30–300 mg/g, n (%) 54 (26.9) 50 (23.8) 204 (20.0) 198 (19.5) 
>300 mg/g, n (%) 27 (13.4) 24 (13.4) 37 (3.6) 31 (3.1) 
Duration of diabetes, years  15.7 (7.8) 15.9 (7.9) 12.1 (7.0) 12.0 (7.3) 
Duration of basal insulin, 
years† 5.7 (4.9) 6.1 (4.5) 5.1 (4.4) 4.9 (4.3) 
Basal daily insulin dose, 
U/kg† 0.67 (0.23) 0.69 (0.26) 0.67 (0.25) 0.67 (0.25) 
  
Total daily insulin dose, 
U/kg‡ 1.22 (0.54) 1.25 (0.45) 1.19 (0.48) 1.19 (0.45) 
Previous antihyperglycemic 
medication excluding 
insulin, n (%) 
154 (74.0) 161 (75.6) 912 (87.8) 919 (88.7) 
Biguanides 134 (64.4) 145 (68.1) 876 (84.3) 877 (84.7) 
Metformin 115 (55.3) 118 (55.4) 702 (67.6) 715 (69.0) 
Metformin hydrochloride 17 (8.2) 28 (13.1) 173 (16.7) 164 (15.8) 
Sulfonylureas 47 (22.6) 39 (18.3) 229 (22.0) 230 (22.2) 
Dipeptidyl peptidase-4 
(DPP-4) inhibitors  
26 (12.5) 31 (14.6) 97 (9.3) 118 (11.4) 
  
Previous insulins and 
analogs, n (%) 
152 (73.1) 150 (70.4) 656 (63.1) 661 (63.8) 
Insulin glargine 134 (64.4) 128 (60.1) 543 (52.3) 579 (55.9) 
Insulin detemir 1 (0.5) 2 (0.9) 7 (0.7) 3 (0.3) 
Insulin degludec 0 (0) 0 (0) 0 (0) 1 (<0.1) 
Any statins, n (%) 149 (71.6) 150 (70.4) 570 (54.9) 591 (57.0) 
Antihypertensive agents, n 
(%) 
185 (88.9) 177 (83.1) 760 (73.1) 774 (74.7) 
Any ACE inhibitors 108 (51.9) 107 (50.2) 463 (44.6) 477 (46.0) 
  
Any other antihypertensive 
agents 
24 (11.5) 26 (12.2) 66 (6.4) 74 (7.0) 
Data are pooled from EDITION 1, 2 and 3, and are presented as mean (SD), unless otherwise indicated. †Only EDITION 1 and 2. 
‡Only EDITION 1. ACE, angiotensin converting enzyme; BMI, body mass index; eGFR, estimated glomerular filtration rate (derived 
using the Modification of Diet in Renal Disease [MDRD] study equation) 
 
  
  
Figure 1A. Mean change in HbA1c from baseline to month 6 according to renal function subgroup (mITT 
population) 
 
 
  
CI, confidence interval; LS, least squares; eGFR, estimated glomerular filtration rate; mITT, modified intent-to-treat; MMRM, mixed 
model for repeated measurements; †Logistic method; p<0.05 corresponds to significant heterogeneity of treatment effect
  
Figure 1B. Percentage of participants achieving HbA1c targets (<7.0 % and <7.5 %) at month 6 (mITT 
population) 
 
eGFR, estimated glomerular filtration rate; mITT, modified intent-to-treat  
  
Figure 2A. Percentage of participants experiencing ≥1 confirmed or severe hypoglycemic event (safety 
population) 
  
eGFR, estimated glomerular filtration rate 
  
Figure 2B. Relative risk of experiencing ≥1 hypoglycemic event with Gla-300 versus Gla-100 by renal 
function subgroup (safety population) 
 
  
CI, confidence interval; eGFR, estimated glomerular filtration rate; †Logistic method; p<0.05 corresponds to significant 
heterogeneity of treatment effect   
  
Figure 3A. Rate of confirmed or severe hypoglycemia by renal function subgroup (safety population) 
 
eGFR, estimated glomerular filtration rate 
  
Figure 3B. Ratio of annualized hypoglycemia event rates by renal function subgroup (safety population) 
 
  
CI, confidence interval; eGFR, estimated glomerular filtration rate; †Logistic method; p<0.05 corresponds to significant 
heterogeneity of treatment effect 
